Profil bibliographique

Azra Durak-Nalbantic

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
56Citations signalées
0Affiliations récentes

Les domaines associés

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCardiac Imaging and DiagnosticsHealth Systems, Economic Evaluations, Quality of LifeCardiovascular Function and Risk Factors

Les publications récentes

Accès ouvert 2025 article OpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

Contains fulltext : 320894.pdf (Publisher’s version ) (Open Access)

fr, us, nl, ar, ca, nz, de (code pays fourni par la source)

25 citations Circulation
Accès ouvert 2024 article OpenAlex

Role of Lactate Dehydrogenase as a Biomarker of Early Cardiac Remodeling: A Cross-Sectional Study

Lejla Brigić, Ehlimana Mušija, Faris Kadić, Mirela Halilčević et autres

BACKGROUND: Lactate dehydrogenase (LDH) isoenzyme assay was used widely in the past to diagnose myocardial infarction (MI). Recent studies show that lactate dehydrogenase seems to be a promising biomarker of adverse left ventricular remodeling. OBJECTIVES: Higher levels of these biomarkers were associated …

ba, id (code pays fourni par la source)

7 citations Cureus
Accès ouvert 2024 article OpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower all-cause death. These benefits …

ca, fr, us, ar, nl, nz, de (code pays fourni par la source)

24 citations European Heart Journal - Cardiovascular Pharmacotherapy
Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.